Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

NEXT STORY
Global Over The Counter/OTC Test Market 2018-2019 & 2024: Leading Players Focus on Organic and Inorganic Growth Strategies
PREV STORY
Corneal Implants Market to hit $500 million By 2025: Global Market Insights, Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Premier Choice Dental & Oral Surgery Center – Belgrade: 4 Reasons Why They Are the Top-Rated Dentist in Belgrade, Montana

author_avatar
NASDAQ Market News

Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

author_avatar
NASDAQ Market News

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

-  In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an ...

author_avatar
NASDAQ Market News